復宏漢霖(02696.HK)公佈中期業績 盈利達約3.86億元 夯實國際化的“研產銷一體”能力
格隆匯8月26日丨復宏漢霖(02696.HK)公吿，截至2024年6月30日止六個月，集團的總收入約人民幣2,746.1百萬元，主要來自藥物銷售，向客户提供的研究與開發服務及授權許可收入，較截至2023年6月30日止六個月約人民幣2,500.5百萬元增加約人民幣245.6百萬元，增長約9.8%。
截至2024年6月30日止六個月，集團的期內盈利約人民幣386.3百萬元，較截至2023年6月30日止六個月盈利約人民幣240.0百萬元，盈利增加約人民幣146.3百萬元，主要是由於核心產品陸續商業化上市並持續銷量擴大所致。
截至2024年8月23日，，集團已有5個產品(23項適應症)成功於中國境內上市銷售，3個產品成功於歐洲、美國、加拿大、澳大利亞、印度尼西亞等國家╱地區獲批上市。2024年初至今，漢曲優獲美國食品藥品管理局(FDA)批准用於乳腺癌輔助治療、轉移性乳腺癌及轉移性胃癌治療，此外，漢曲優的上市註冊申請(NDS)獲加拿大衞生部(Health Canada)批准；漢斯狀海外商業化版圖成功新添柬埔寨、泰國；漢利康亦獲批准於祕魯上市，集團「出海」成果日益凸顯。
截至最後實際可行日期，集團管線共計50餘個分子和14個研發平台，藥物形式覆蓋單抗、雙抗、抗體偶聯藥物、重組蛋白、小分子偶聯藥物等。
集團重視臨牀前項目儲備，於報吿期內成功推動GARP/TGF- β 1、TIGIT+PD-1+VEGF靶點項目的臨牀試驗申請(IND)獲得批准並順利進入臨牀研究。
集團具備商業化產能合計48,000升(包括徐匯基地商業化產能24,000升、松江基地(一)商業化產能24,000升)。徐匯基地於報吿期內順利就漢斯狀、漢曲優、漢達遠等產品完成多次海外客户審計；松江基地(一)已經順利通過美國食品藥品監督局(FDA)關於注射用曲妥珠單抗HERCESSITM(中國商品名：漢曲優，歐洲商品名：Zercepac)的許可前檢查(PLI)，標誌着相關生產場地和設施已獲得美國GMP認證；松江基地(二)一期項目第三階段已於報吿期內完成主體結構封頂。
下半年，集團將持續從臨牀需求出發，深耕腫瘤、自身免疫性疾病等領域，深化產品創新、市場拓展和國際合作，夯實國際化的「研產銷一體」能力，在更具規模化、國際化、有持續盈利能力的Biopharma舞台穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
